SLC2A1 and breast cancer: In present study, we showed that LRS treatment down-regulated SLC2A1 expression level, implicating the therapeutic value of L. rhamnosus. Interestingly, the result of the previous investigations, indicating that inhibition of glycolysis might serve a future modality for breast cancer therapy (26), provides further supports for application of lactobacilli in this regard.